Ionis Pharms Inc Drug Patent Portfolio
Ionis Pharms Inc owns 2 orange book drugs protected by 8 US patents Given below is the list of Ionis Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10294477 | 01 May, 2035 | Active | |
| US9670492 | 28 Aug, 2034 | Active | |
| US9127276 | Conjugated antisense compounds and their use | 01 May, 2034 | Active |
| US9181549 | Conjugated antisense compounds and their use | 01 May, 2034 | Active |
| US9163239 | Compositions and methods for modulating apolipoprotein C-III expression | 01 May, 2034 | Active |
| US9593333 | Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations | 14 Feb, 2034 | Active |
| US9315811 | 21 Oct, 2032 | Active | |
| US9157082 | Modulation of apolipoprotein CIII (ApoCIII) expression | 27 Apr, 2032 | Active |
Ionis Pharms Inc's Family Patents
Ionis Pharms Inc Drug List
Given below is the complete list of Ionis Pharms Inc's drugs and the patents protecting them.
1. Dawnzera (autoinjector)
Dawnzera (autoinjector) is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10294477 |
01 May, 2035
(9 years from now)
| Active | |
| US9670492 |
28 Aug, 2034
(8 years from now)
| Active | |
| US9127276 | Conjugated antisense compounds and their use |
01 May, 2034
(8 years from now)
| Active |
| US9181549 | Conjugated antisense compounds and their use |
01 May, 2034
(8 years from now)
| Active |
| US9315811 |
21 Oct, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dawnzera (autoinjector)'s drug page
2. Tryngolza (autoinjector)
Tryngolza (autoinjector) is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9127276 | Conjugated antisense compounds and their use |
01 May, 2034
(8 years from now)
| Active |
| US9163239 | Compositions and methods for modulating apolipoprotein C-III expression |
01 May, 2034
(8 years from now)
| Active |
| US9181549 | Conjugated antisense compounds and their use |
01 May, 2034
(8 years from now)
| Active |
| US9593333 | Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations |
14 Feb, 2034
(8 years from now)
| Active |
| US9157082 | Modulation of apolipoprotein CIII (ApoCIII) expression |
27 Apr, 2032
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tryngolza (autoinjector)'s drug page